VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HCA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HCAHCA Healthcare, Inc.
$501.19$103.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHCAFinancials

HCA Healthcare, Inc. (HCA) Income Statement

30Y historyFree accessUpdated daily

Revenue growth has slowed toward mid-single digits, with 2026Q3 revenue of $19.8B up only 3.6% and net margin of 8.0% versus 8.8% a year earlier, suggesting modest margin pressure.

Income StatementBalance SheetCash FlowRatios

HCA Income Statement

Annual statement

HCA Income Statement

HCA Healthcare, Inc. (HCA) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue78.7B75.6B70.6B64.97B60.23B58.75B51.53B51.34B46.68B43.61B41.49B39.68B36.92B34.18B33.01B32.51B30.68B30.05B28.37B26.86B25.48B24.45B23.5B21.81B19.73B17.95B16.67B16.66B18.68B18.82B19.91B
Revenue Growth %5.82%7.08%8.67%7.86%2.52%14.01%0.38%9.98%7.02%5.12%4.57%7.48%8%3.54%1.56%5.94%2.1%5.91%5.64%5.42%4.18%4.06%7.77%10.54%9.89%7.7%0.08%-10.83%-0.73%-5.47%12.51%
Cost of Goods Sold61.63B44.23B41.92B39.39B37.06B36.26B8.37B8.48B7.72B7.32B6.93B6.64B6.26B5.97B5.72B5.18B4.96B4.87B4.62B4.39B4.32B4.13B3.9B00000007.54B
COGS % of Revenue-58.5%59.38%60.63%61.52%61.72%16.24%16.52%16.55%16.77%16.71%16.73%16.96%17.47%17.32%15.93%16.17%16.2%16.28%16.36%16.96%16.87%16.6%-------37.87%
Gross Profit17.07B31.37B28.68B25.58B23.18B22.49B43.16B42.85B38.95B36.3B34.56B33.04B30.66B28.21B27.3B24.5B23.07B25.18B23.75B22.46B21.16B20.33B19.6B000000011.25B
Gross Margin %21.69%41.5%40.62%39.37%38.48%38.28%83.76%83.48%83.45%83.23%83.29%83.27%83.04%82.53%82.68%75.38%75.2%83.8%83.72%83.64%83.04%83.13%83.4%-------56.49%
Gross Profit Growth %-9.4%12.12%10.36%3.05%-47.89%0.72%10.02%7.31%5.04%4.59%7.78%8.66%3.36%11.4%6.19%-8.38%6.02%5.75%6.18%4.06%3.71%--------100%8.14%
Operating Expenses5B19.41B18.13B15.95B14.12B12.81B35.9B35.64B32.31B30.24B28.36B27.07B25.09B23.42B22.48B20.16B18.91B21.38B20.82B19.51B18.32B17.43B16.89B19.01B17.68B15.73B117M220M1.79B17.65B8.35B
OpEx % of Revenue-25.67%25.68%24.55%23.45%21.81%69.67%69.42%69.22%69.34%68.35%68.24%67.96%68.52%68.09%62.03%61.63%71.15%73.37%72.65%71.9%71.25%71.84%87.17%89.61%87.61%0.7%1.32%9.58%93.78%41.93%
Selling, General & Admin24.43B8B31.17B29.49B27.68B26.78B23.87B23.56B21.43B20.06B18.9B18.11B16.64B15.65B15.09B13.44B12.48B11.96B11.44B10.71B10.41B9.93B9.42B8.68B7.95B7.28B6.64B6.75B7.81B7.63B7.21B
SG&A % of Revenue-10.58%44.15%45.39%45.96%45.58%46.33%45.89%45.9%45.99%45.55%45.66%45.08%45.77%45.71%41.35%40.69%39.79%40.32%39.89%40.86%40.6%40.08%39.81%40.31%40.54%39.83%40.52%41.81%40.55%36.19%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses-2M11.41B-13.04B-13.54B-13.56B-13.96B12.03B12.08B10.89B10.18B9.46B8.96B8.45B7.77B7.39B6.72B6.42B9.43B9.38B8.8B7.91B7.5B7.47B10.33B9.73B8.45B-6.52B-6.53B-6.02B10.02B1.14B
Operating Income12.07B11.96B10.55B9.63B9.05B9.68B7.26B7.22B6.64B6.06B6.2B5.96B5.57B4.79B4.82B4.34B4.17B3.8B2.94B2.95B2.84B2.9B2.72B2.8B2.05B2.23B16.55B16.44B16.89B1.17B2.9B
Operating Margin %15.34%15.83%14.94%14.82%15.03%16.47%14.09%14.06%14.23%13.89%14.94%15.03%15.07%14.02%14.59%13.35%13.57%12.65%10.34%10.99%11.13%11.87%11.56%12.83%10.39%12.39%99.3%98.68%90.42%6.22%14.56%
Operating Income Growth %-13.44%9.56%6.34%-6.46%33.27%0.61%8.67%9.66%-2.27%3.91%7.19%16.13%-0.5%11.02%4.15%9.58%29.51%-0.58%4.09%-2.34%6.92%-2.9%36.51%-7.91%-86.56%0.71%-2.69%1342.53%-59.59%9.61%
EBITDA15.81B15.49B13.86B12.7B12.02B12.53B9.98B9.81B8.92B8.19B8.16B7.87B7.38B6.54B6.5B5.8B5.59B5.23B4.35B4.38B4.23B4.28B3.97B3.91B3.06B3.27B17.59B17.53B18.14B2.41B4.05B
EBITDA Margin %20.09%20.49%19.63%19.55%19.96%21.33%19.37%19.12%19.11%18.77%19.68%19.83%20%19.15%19.67%17.85%18.21%17.39%15.33%16.3%16.59%17.49%16.88%17.92%15.51%18.23%105.49%105.25%97.1%12.8%20.36%
EBITDA Growth %4.7%11.75%9.09%5.67%-4.06%25.52%1.72%10.02%8.94%0.29%3.75%6.55%12.83%0.77%11.92%3.88%6.89%20.11%-0.62%3.57%-1.19%7.87%1.46%27.79%-6.54%-81.39%0.31%-3.35%652.97%-40.56%11.81%
D&A (Non-Cash Add-back)3.74B3.52B3.31B3.08B2.97B2.85B2.72B2.6B2.28B2.13B1.97B1.9B1.82B1.75B1.68B1.47B1.42B1.43B1.42B1.43B1.39B1.37B1.25B1.11B1.01B1.05B1.03B1.09B1.25B1.24B1.16B
EBIT12.16B12.08B10.58B9.64B10.32B11.4B7.01B7.07B7.09B6.07B6.52B5.62B5.22B4.79B4.69B5.6B4.33B3.99B3.19B3.4B2.62B2.8B2.54B2.8B2.05B2.23B16.55B16.44B16.89B1.17B2.9B
Net Interest Income-2.36B-2.25B-2.06B-1.94B-1.74B-1.53B-1.56B-1.84B-1.76B-1.67B-1.6B-1.54B-1.61B-1.72B-1.68B-1.7B-2.1B-1.64B-2.02B-2.21B-955M-655M-563M00000000
Interest Income0000000000000000000000000000000
Interest Expense2.36B2.25B2.06B1.94B1.74B1.53B1.56B1.84B1.76B1.67B1.6B1.54B1.61B1.72B1.68B1.7B2.1B1.64B2.02B2.21B955M655M563M00000000
Other Income/Expense-2.25B-2.13B-2.02B-1.92B-473M155M-1.83B-1.97B-1.31B-1.68B-1.39B-2.01B-2.08B-1.85B-1.92B-777M-1.93B-1.8B-1.76B-1.76B-1.17B-755M-743M-641M-594M-720M-16.04B-15.21B-15.81B-783M-456M
Pretax Income9.82B9.83B8.52B7.71B8.58B9.83B5.43B5.24B5.33B4.38B4.81B3.96B3.48B2.95B2.89B3.56B2.23B2B1.17B1.19B1.66B2.15B1.97B2.16B1.46B1.5B516M1.23B1.08B388M2.44B
Pretax Margin %12.48%13.01%12.07%11.86%14.24%16.74%10.54%10.22%11.43%10.04%11.59%9.97%9.43%8.62%8.77%10.95%7.27%6.66%4.12%4.43%6.52%8.79%8.39%9.89%7.37%8.38%3.1%7.37%5.79%2.06%12.27%
Income Tax2.02B2.05B1.87B1.61B1.75B2.11B1.04B1.1B946M1.64B1.38B1.26B1.11B950M888M719M658M627M268M316M626M725M727M824M622M602M297M570M549M206M981M
Effective Tax Rate %20.6%20.85%21.89%20.96%20.35%21.48%19.21%20.96%17.73%37.39%28.65%31.87%31.83%32.25%30.68%20.19%29.49%31.32%22.91%26.55%37.67%33.74%36.85%38.22%42.75%40%57.56%46.45%50.79%53.09%40.17%
Net Income6.78B6.78B5.76B5.24B5.64B6.96B3.75B3.5B3.79B2.22B2.89B2.13B1.88B1.56B1.6B2.46B1.21B1.05B673M874M1.04B1.42B1.25B1.33B833M886M292M740M471M-305M1.5B
Net Margin %8.61%8.97%8.16%8.07%9.37%11.84%7.28%6.83%8.11%5.08%6.97%5.37%5.08%4.55%4.86%7.58%3.93%3.51%2.37%3.25%4.07%5.82%5.3%6.11%4.22%4.94%1.75%4.44%2.52%-1.62%7.56%
Net Income Growth %6.81%17.78%9.88%-7.11%-18.88%85.3%7.1%-7.45%70.89%-23.32%35.74%13.55%20.5%-3.05%-34.89%104.23%14.52%56.61%-23%-15.64%-27.25%14.29%-6.46%59.9%-5.98%203.42%-60.54%57.11%254.43%-120.27%56.61%
Net Income (Continuing)7.8B7.78B6.66B6.09B6.83B7.72B4.39B4.14B4.39B2.74B3.43B2.7B2.37B2B2.01B2.84B1.57B1.38B902M874M1.04B1.42B1.25B1.48B981M903M208M683M401M182M1.46B
Discontinued Operations0000000000000000000000000000-153M-431M44M
Minority Interest3.48B3.26B3.05B2.83B2.69B2.42B2.32B2.24B2.03B1.81B1.67B1.55B1.4B1.34B1.32B1.24B1.13B1.01B995M938M907M828M809M680M611M563M572M763M765M836M836M
EPS (Diluted)31.2028.3822.0018.9619.1521.1610.9310.0710.665.957.304.994.163.373.494.972.763.021.932.512.533.182.582.611.591.650.401.110.73-0.462.22
EPS Growth %16.66%29%16.03%-0.99%-9.5%93.6%8.54%-5.53%79.16%-18.49%46.29%19.95%23.44%-3.44%-29.78%80.07%-8.61%56.48%-23.11%-0.79%-20.44%23.26%-1.15%64.15%-3.64%312.5%-63.96%52.05%258.7%-120.72%55.24%
EPS (Basic)-28.6222.2719.2419.4421.5111.0810.2711.046.337.805.344.463.543.625.172.833.081.972.562.573.242.622.661.631.690.391.120.73-0.462.24
Diluted Shares Outstanding217.21M230.71M261.81M276.41M294.67M328.75M345.37M348.23M355.3M372.22M395.85M426.72M450.35M461.91M459.4M495.94M437.35M348.71M348.71M348.71M410.2M447.5M483.66M510.34M523.9M536.97M553.93M666.67M645.21M663.04M677.93M
Basic Shares Outstanding222.2M230.71M258.6M272.4M290.35M323.31M339.43M341.21M342.9M350.09M370.54M398.74M420.48M439.6M443.2M476.61M426.42M341.93M341.93M341.93M403.4M440.02M475.62M500.75M511.04M524.26M547.51M660.71M645.21M663.04M671.88M
Dividend Payout Ratio-10.01%11.98%12.61%11.57%8.97%4.08%15.69%12.86%---0.37%1.03%196.14%1.26%352.69%---19.4%18.12%15.97%2.93%4.8%4.74%15.07%---3.59%

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Labor cost and reimbursement pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Moderating Toward Mid-Single Digits

Based on reported quarterly figures, HCA's revenue growth slowed from 10.3% in Q2 2024 to 3.6% in Q3 2026, suggesting the high-single-digit volume recovery of the prior cycle is losing momentum.

The deceleration from double-digit growth to low-single digits suggests volume gains are normalizing rather than compounding. Investors should monitor whether same-facility admissions and case mix can sustain top-line expansion without relying on pricing. The data does not isolate organic versus acquired growth, which limits conclusions about underlying durability.

Reported Margin Structure Requires Reclassification Context

Reported gross margin fell from roughly 41% through 2025 to about 15% in 2026 quarters, a shift that appears driven by a change in how cost lines are presented rather than by an observable operating deterioration.

Operating margin tracks gross margin almost exactly in the 2026 periods, which is consistent with a reporting reclassification that moved costs into a different line. Treating the drop as economic compression would likely overstate the deterioration. Comparability against peers such as Tenet and Universal Health Services should be verified against consistent line definitions before drawing margin conclusions.

EPS Growth Outpaces Net Income Trend

Based on EDBL-style reported figures, diluted EPS rose 44.6% year over year in Q4 2025 while revenue grew only 6.7%, indicating buybacks and share count reduction likely contributed materially to per-share results.

The gap between EPS and net income growth suggests repurchase activity is a meaningful driver of per-share earnings. In Q2 2026 EPS of $7.62 beat the cited $6.78 expectation, but the lowered full-year guidance tempers how much weight that single quarter should carry. Stock-based compensation is largely absent from the reported 2026 data, so its impact on earnings quality cannot be assessed for those periods.

Guidance Cut Undercuts Headline Beat

As reported in recent filings, the Q2 2026 EPS beat of $7.62 against $6.78 expected was paired with a full-year guidance reduction, which may signal decelerating momentum in the back half of the year.

A headline beat followed by lower forward guidance is a pattern bears typically cite as evidence of one-time strength masking weaker trends. The risk is that operating leverage visible in prior quarters reverses if labor costs or payor mix shift unfavorably. Site-neutral payment proposals add a policy overhang that could compress outpatient pricing, which warrants further investigation.

HCA — Frequently Asked Questions

Quick answers to the most common questions about buying HCA stock.

What was HCA Healthcare, Inc.'s (HCA) revenue in 2025?

For fiscal year 2025, HCA Healthcare, Inc. (HCA) reported total revenue of $75.60B. This represents a 279.7% increase compared to $19.91B in 1996.

Is HCA Healthcare, Inc. (HCA) profitable?

HCA Healthcare, Inc. (HCA) is profitable, generating $6.78B in net income for the fiscal year ending 2025 with a net profit margin of 9.0%.

What is HCA Healthcare, Inc.'s operating profit margin?

HCA Healthcare, Inc. (HCA) reported an operating income of $11.96B, resulting in an operating profit margin of 15.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is HCA Healthcare, Inc.'s gross profit and gross margin?

HCA Healthcare, Inc. (HCA) generated $31.37B in gross profit for the year, representing a gross profit margin of 41.5%. This demonstrates the company's core pricing power and production efficiency.